Ian D. Davis

28.9k citations

364 papers · 11.2k indexed · 1 hit paper · h-index 52

Impact in

Pulmonary and Respiratory Medicine top 0.2%
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research

Papers in

Pulmonary and Respiratory Medicine 186
- Prostate Cancer Treatment and Research 95
- Renal cell carcinoma treatment 70
- Prostate Cancer Diagnosis and Treatment 45
Oncology 119
- Cancer Immunotherapy and Biomarkers 41

Co-authors: Jonathan Cebon Terry Cannon Piers Blaikie Ben Wisner Lauren McCann Lini Pandite Cezary Szczylik Cora N. Sternberg
Journals: Journal of Clinical Oncology (92 papers)British Journal of Urology (28 papers)Annals of Oncology (18 papers)Clinical Cancer Research (12 papers)The Journal of Urology (7 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Ian D. Davis

345 papers receiving 10.9k citations

Hit Papers

align trajectories log scale

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial 2010 · 1.9k citations

Peers

Countries citing papers authored by Ian D. Davis

Since Specialization

Citations

This map shows the geographic impact of Ian D. Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian D. Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian D. Davis more than expected).

Fields of papers citing papers by Ian D. Davis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian D. Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian D. Davis. The network helps show where Ian D. Davis may publish in the future.

Co-authors

The 25 scholars most cited alongside Ian D. Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ian D. Davis Line = papers co-authored together Ian D. Davis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Challenges of estimating treatment effects after a positive interim analysis European Journal of Cancer ·R.A.MóN.E. PIñEro, Ian C. Marschner, 和直柴田, Christopher J. Sweeney, Ian D. Davis, Martin R. Stockler, Andrew Martin	2024	0
2	A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity World Journal of Urology ·Avşin Öztaş, 靖子鈴木, Harley Daniel, Ian D. Davis, Shomik Sengupta	2024	0
3	Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304). Journal of Clinical Oncology ·Liyan Chen, B. Sakila, Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney, (unknown)	2024	3
4	1886P Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601) Annals of Oncology ·Craig Gedye, Carole A. Harris, Martin R. Stockler, 美千代二見, Adamade Sylvanus Simon, Jeffrey C. Goh, Andrew Martin, Craig Underhill, David Pook, Laurence E. Krieger, Ganessan Kichenadasse, Abhishek Joshi, Shalini Subramaniam, Myeong-Sook Kim, Christoph Hauptmann, Anthony M. Joshua, Guy C. Toner, P. Vasey, Prashanth Prithviraj, Ian D. Davis	2023	0
5	1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304) Annals of Oncology ·Lisa G. Horvath, Ian D. Davis, Andrew Martin, 拓斗林, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John A. McCaffrey, Ray McDermott, Nicola Jane Lawrence, Mark Frydenberg, S. Chowdhury, K.N. Chi, Martin R. Stockler, Christopher J. Sweeney	2023	2
6	Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial Cancer Imaging ·Samuel Tremblay, 张虎成张征田, Andrew Weickhardt, Ian D. Davis, Andrew M. Scott, Rodney J. Hicks, Ur Metser, Sue Chua, Gabrielle Chabaud, Shonit Punwani, Heather Payne, Nina Tunariu, Bao Ho, S.V. Camacho-Martinez, Aida Gadouche, Glenn Bauman, Louise Emmett, Frédéric Pouliot	2023	1
7	The Dedicated Imaging Post‐Prostatectomy for Enhanced Radiotherapy outcomes ( DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low‐risk biochemical recurrence after radical prostatectomy British Journal of Urology ·Matthew J. Roberts, Louis Fieser, Ian D. Davis, 汝钤陆, Scott Williams, Jarad Martin, Michael S. Hofman, George Hruby, Renu Eapen, Piyush B. Moradiya, Nathan Papa, Richard De Abreu Lourenço, Haryana M. Dhillon, Ray Allen, Luigi Fiorillo, Vijit Chahar, Louise Emmett, (unknown)	2023	1
8	Treatment de‐intensification for low‐risk biochemical recurrence after radical prostatectomy: rational or risky? British Journal of Urology ·Matthew J. Roberts, George Hruby, Andrew Kneebone, Jarad Martin, Scott Williams, Mark Frydenberg, Declan G. Murphy, 秦丽莉, John Yaxley, Michael S. Hofman, Ian D. Davis, Louise Emmett	2023	2
9	Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations JCO Oncology Practice ·Louis Fieser, Jeremy Lewin, Andrew Weickhardt, James Lynam, Shirley Wong, Peter Grimison, Shomik Sengupta, Filippa Marotta, Francis Parnis, Patricia Bastick, David Campbell, Aaron R. Hansen, Kusuma Kasapura Shivashankar, Margaret McJannett, Martin R. Stockler, Peter Gibbs, Guy C. Toner, Ian D. Davis, Ben Tran, Karl Rasmus Sveding	2023	3
10	External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. Apollo (University of Cambridge) ·Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, A.W.S. Ritchie, Richard Kaplan, J. P. Lipton, Ian D. Davis, Martin R. Stockler, Laurence Albigès, Bernard Escudier, James Larkin, Steven Joniau, Barry W. Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh Parmar, Patrick Royston, Angela Meade	2022	10
11	Impacts of the COVID‐19 pandemic on early detection of prostate cancer in Australia British Journal of Urology ·허정화, Joshua Kealey, Ian D. Davis, Shomik Sengupta	2021	5
12	Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor–treated Metastatic Castration-resistant Prostate Cancer European Urology Focus ·Heidi Fettke, Edmond M. Kwan, Patricia Bukczynska, Nicole Ng, Tú Nguyen‐Dumont, Melissa C. Southey, Ian D. Davis, Andrew Mant, Phillip Parente, Evelina L. Fortajada, Christine Hauser, Arun Azad	2020	13
13	Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer European Urology Focus ·Edmond M. Kwan, Heidi Fettke, Maria Docanto, Sarah Q. To, Patricia Bukczynska, Andrew Mant, David Pook, Nicole Ng, Shojiro Omata, Stefano Mangiola, Eva Segelov, Kate Mahon, Ian D. Davis, Phillip Parente, Carmel Pezaro, Andrew Screen, Lisa G. Horvath, Arun Azad	2019	11
14	BCG + Mitomycin trial for high‐risk non‐muscle‐invasive bladder cancer: progress report and lessons learned British Journal of Urology ·Dickon Hayne, Martin R. Stockler, Rengasamy Thatha Desikan, Nicola Jane Lawrence, Andrew Martin, Shomik Sengupta, Ian D. Davis	2017	1
15	Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial Journal of Clinical Oncology ·Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg Gladkov, Alexander Kavina, Juan José Zarbá, Chen Mei, Lauren McCann, Lini Pandite, Debasish Roychowdhury, Robert E. Hawkins Hit paper breakdown →	2010	1940
16	Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial Clinical Cancer Research ·Ian D. Davis, Jodie Underhill, Richard Kefford, Michael Millward, Jonathan Cebon, Birte K. Skrumsager, Ulrik Mouritzen, Lasse Tengbjerg Hansen, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Paul E.G. Kristjansen, Grant A. McArthur	2009	120
17	Predicting Clinical Outcome through Molecular Profiling in Stage III Melanoma Clinical Cancer Research ·Thomas John, Michael A. Black, Tumi Toro, M Johnston, Craig Gedye, Ian D. Davis, Parry Guilford, Jonathan Cebon	2008	44
18	The Regulatory T Cell–Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells Cancer Research ·Lisa M. Ebert, Bee Shin Tan, Judy Browning, Suzanne Svobodová, Sarah E. Russell, Katandria Love Johnson, Craig Gedye, Denis J. Moss, Sweet Ping Ng, Duncan MacGregor, Ian D. Davis, Jonathan Cebon, Weisan Chen	2008	152
19	An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma Clinical Cancer Research ·Ian D. Davis, Birte K. Skrumsager, Jonathan Cebon, Theo Nicholaou, John Barlow, Niels Peter Hundahl Møller, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Peter Thygesen, Grant A. McArthur	2007	132
20	Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells Blood ·Max Schnurr, Tracey Toy, Amanda Shin, Gunther Hartmann, Simon Rothenfußer, 高田泰久, Ian D. Davis, Jonathan Cebon, Eugene Maraskovsky	2003	150

About Ian D. Davis

Ian D. Davis is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 364 papers that have together received 11.2k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (95 papers), Renal cell carcinoma treatment (70 papers), Immunotherapy and Immune Responses (64 papers), Prostate Cancer Diagnosis and Treatment (45 papers), Cancer Genomics and Diagnostics (44 papers), Bladder and Urothelial Cancer Treatments (44 papers), Radiopharmaceutical Chemistry and Applications (42 papers) and Cancer Immunotherapy and Biomarkers (41 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.6k citations), Oncology (3.7k citations), Cancer Research (1.9k citations), Immunology (2.6k citations) and Molecular Biology (3.8k citations). Ian D. Davis has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Jonathan Cebon, Terry Cannon, Piers Blaikie, Ben Wisner, Lauren McCann, Lini Pandite, Cezary Szczylik, Cora N. Sternberg, Robert E. Hawkins and John Wagstaff. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Urology, Annals of Oncology, Clinical Cancer Research and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact